Nolvasan® Cap-Tabs® — veterinary medication

Overview

Source: Animal Drugs @ FDA

Proprietary name

Nolvasan® Cap-Tabs®

Active ingredient

Chlorhexidine Hydrochloride

Application type

NADA

Sponsor

Zoetis Inc.

Applications on record

1

First published

June 1, 2016

Adverse event reports

Source: openFDA VeDDRA

452

Reports mentioning this ingredient

October 2, 1989 – March 24, 2026

86

Classified serious

per reporter assessment

53

Lack of expected efficacy

resistance signal

3

Human operator exposure

needle-stick or splash

Not a risk measure. Veterinary adverse event reports are influenced by how many animals are treated, reporting practice and product age. Reports do not establish that the product caused the event, and a single report can cover an entire herd or flock. Attribution here is by active ingredient because the source dataset redacts brand names.

Attributed by active ingredient “CHLORHEXIDINE”. Green Book ingredient names and VeDDRA ingredient names do not always agree exactly, so attribution is approximate and labelled as such.

Reported reactions

Source: openFDA VeDDRA

Clinical signs coded in the VICH VeDDRA four-level hierarchy, most frequent first.

Reaction terms reported for this ingredient, by report count.
Reaction (VeDDRA term)	Reports	Relative frequency
Application site erythema	63
Application site pain	25
Application site inflammation	22
Application site pruritus	19
Application site reddening	19
Tubes, Leaking	18
Application site irritation	18
Pruritus	13
Vocalisation	13
Missing Cap	11
Lack of efficacy - NOS	11
Vomiting	11
Uncomfortable	9
Licking at application site	9
Erythema (for urticaria see Immune SOC)	8
Lethargy (see also Central nervous system depression in Neurological)	8
Behavioural disorder NOS	6
Unclassifiable adverse event	5
Pacing	5
Hypersalivation	5

Species affected

Source: openFDA VeDDRA

Dog 340 Cat 53 Human 14 Cattle 5 Horse 4 Other 1 Goat 1 Guinea Pig 1

Regulatory context

New Animal Drug Application (NADA). A pioneer approval evaluated for target animal safety, therapeutic effectiveness, manufacturing controls and — for food-producing species — human food safety including residue depletion.

Extra-label use in food-producing animals is governed by the Animal Medicinal Drug Use Clarification Act of 1994 (AMDUCA) and 21 CFR Part 530. It requires a valid veterinarian-client-patient relationship and is prohibited outright for certain drug classes. Withdrawal times are determined by FARAD, not by this index.

Sources for this page

Animal Drugs @ FDA	FDA CVM	Applications, sponsor, status, withdrawal
Animal & Veterinary Events	FDA CVM	VeDDRA adverse event aggregates by active ingredient